Pfizer announced today (8/7) that it has signed a multiyear agreement for Gilead’s remdesivir, a treatment for COVID-19. With Gilead aiming to produce enough remdesivir to treat more than 2 million patients by the end of the year, and agreeing to send almost the entirety of its supply to the United States through September. Pfizer is also working with biotech company BioNTech to create a vaccine for COVID-19, separately from their agreement with Gilead. It is not clear at this time if Pfizer’s manufacturing of the drug will only be for the US market.
Read more here.